Cervicitis News and Research

RSS

Extensively drug-resistant Neisseria gonorrhoeae strain recently identified in Austria

Given that there is no vaccine available against gonorrhea, diagnosing this sexually transmitted infection early, treating it effectively and notifying sexual partners are cornerstones of controlling disease spread.

16 Jun 2022

ACTG initiates clinical trial to evaluate treatment for COVID-19

The AIDS Clinical Trials Group, the world's largest and longest established HIV research network, today announced the initiation of ACTG 5395, a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (which is caused by infection with the virus SARS-CoV-2).

14 May 2020

FDA authorizes marketing of new test to aid in the diagnosis of M. gen. infections

The U.S. Food and Drug Administration today permitted marketing of a new test to aid in the diagnosis of a sexually-transmitted infection called Mycoplasma genitalium (M. gen.).

23 Jan 2019

FDA grants clearance to Hologic’s assay for detection of common sexually transmitted infections

Hologic, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its Aptima Mycoplasma genitalium assay, the first and only FDA-cleared test to detect this under-recognized but increasingly common sexually transmitted infection (STI).

23 Jan 2019

Scientists discover cell adhesion mechanism used by mycoplasma genitalium

Researchers from the Molecular Biology Institute of Barcelona and the Institute of Biotechnology and Biomedicine have discovered the mechanism by which the bacterium Mycoplasma genitalium) adheres to human cells.

29 Oct 2018

Pelvic exams do not improve physician's ability to diagnose STDs in adolescent female patients

A pelvic exam does not improve a physician's ability to diagnose certain sexually transmitted diseases in adolescent female patients.

3 Jul 2018

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Common sexually transmitted bacterial infection more than doubles risk of HIV

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, according to a study by researchers at RTI International.

11 Mar 2012

Infection with M. genitalium may double African women's HIV risk

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, reports a study in the March issue of AIDS.

9 Mar 2012

Gen-Probe receives FDA marketing clearance for APTIMA Trichomonas vaginalis assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system.

20 Apr 2011

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

Gen-Probe submits 510(k) application to FDA for APTIMA Trichomonas vaginalis assay on TIGRIS system

Gen-Probe Incorporated announced today that the Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system.

5 Oct 2010

Fred Hutchinson Cancer Center research team wins 2010 BioFlux Innovation Award

Fluxion Biosciences, Inc. announced today that a research team from Fred Hutchinson Cancer Center has won the 2010 BioFlux Innovation Award competition. Laura Sycuro, Ph.D., a post-doctoral research fellow in the lab of David Fredricks, M.D., authored the winning submission which focuses on screening and characterizing bacterial strains involved in biofilm-related infections known to affect women's reproductive health.

From Fluxion Biosciences 17 Sep 2010

FDA approves treatment for bacterial vaginosis

Mission Pharmacal has announced that the U.S. Food and Drug Administration (FDA) approved Tindamax (tinidazole) for the treatment of bacterial vaginosis (BV), the most common vaginal infection among women of childbearing age in the United States.

28 May 2007